athenahealth, Inc. Reports Fourth Quarter and Full Year 2013 Results
Q4 2013 Financial Results
| |
| • | 48% Revenue Growth Over Fourth Quarter of 2012 |
| |
| • | Non-GAAP Adjusted Operating Income of $34.1 million |
| |
| • | GAAP Net Income of $13.1 million, or $0.34 Per Diluted Share |
| |
| • | Non-GAAP Adjusted Net Income of $22.1 million, or $0.57 Per Diluted Share |
Full Year 2013 Financial Results
| |
| • | 41% Revenue Growth Over Full Year 2012 |
| |
| • | Non-GAAP Adjusted Operating Income of $74.0 million
|
| |
| • | GAAP Net Income of $2.6 million, or $0.07 Per Diluted Share |
| |
| • | Non-GAAP Adjusted Net Income of $44.3 million, or $1.16 Per Diluted Share |
WATERTOWN, MA – February 6, 2014 - athenahealth, Inc. (NASDAQ: ATHN) (“athenahealth” or “we”), a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination, today announced financial and operational results for the fourth quarter and full year 2013. We will conduct a conference call tomorrow, Friday, February 7, 2014, at 8:00 a.m. Eastern Time to discuss these results and management’s outlook for future financial and operational performance.
| |
| • | Total revenue for the three months ended December 31, 2013, was $171.6 million, compared to $116.3 million in the same period last year, an increase of 48%. |
| |
| ◦ | Excluding revenue from Epocrates-branded services of $18.9 million and other revenue consisting of third-party tenant revenue of $3.7 million, core athenahealth revenue was $149.0 million, an increase of 28% over for the three months ended December 31, 2012. |
| |
| • | Total revenue for full year 2013 was $595.0 million, compared to full year 2012 revenue of $422.3 million, an increase of 41%. |
| |
| ◦ | Excluding revenue from Epocrates-branded services of $52.4 million and other revenue consisting of third-party tenant revenue of $9.7 million, core athenahealth revenue was $532.9 million, an increase of 26% over full year 2012. |
“2013 was a pivotal year for athenahealth. We made marked progress on the evolution of the caregiver user experience, demonstrated resounding success in the enterprise segment, and have begun to revolutionize client on-boarding and performance management with the launch of our nerve centers,” said Jonathan Bush, athenahealth’s Chairman and Chief Executive Officer. “While information exchange in health care remains mostly an abstract concept, we have made considerable advancements towards our vision of becoming the nation’s health information cloud. Following a vertical learning curve, we are innovating and disrupting the status quo, helping our clients be the best at knowing their patients, knowing their problems and for the first time, turning care coordination from a noun into a verb.”
| |
| • | For the three months ended December 31, 2013, Non-GAAP Adjusted Gross Margin was 66.2%, up from 63.4% in the same period last year. |
| |
| • | For the three months ended December 31, 2013, Non-GAAP Adjusted Operating Income was $34.1 million, or 19.9% of total revenue, compared to Non-GAAP Adjusted Operating Income of $19.7 million, or 16.9% of total revenue, in the same period last year. |
| |
| ◦ | Non-GAAP Adjusted Operating Income excludes $0.4 million of integration costs relating to the acquisition of Epocrates which closed on March 12, 2013. |
| |
| • | For the three months ended December 31, 2013, GAAP Net Income was $13.1 million, or $0.34 per diluted share, compared to $5.9 million, or $0.16 per diluted share, in the same period last year. |
| |
| • | For the three months ended December 31, 2013, Non-GAAP Adjusted Net Income was $22.1 million, or $0.57 per diluted share, compared to $10.8 million, or $0.29 per diluted share, in the same period last year. |
“The athenahealth team delivered another great year. We grew our physician network by 28%, achieved our 30% bookings growth goal for our core business and made significant investments in innovation to stay ahead of the ever-changing health care marketplace,” said Tim Adams, athenahealth’s Chief Financial Officer. “Each day we are expanding our capabilities in the delivery of health care information technology services into our multi-billion dollar market opportunity. We are thrilled with the progress we have made in 2013 and are well-positioned to continue our success in 2014 and over the long-term.”
| |
| • | For the year ended December 31, 2013, Non-GAAP Adjusted Gross Margin was 63.0%, up from 62.6% for the year ended December 31, 2012. |
| |
| • | For the year ended December 31, 2013, Non-GAAP Adjusted Operating Income was $74.0 million, or 12.4% of total revenue, compared to Non-GAAP Adjusted Operating Income of $65.5 million, or 15.5% of total revenue, for the year ended December 31, 2012. |
| |
| • | For the year ended December 31, 2013, GAAP Net Income was $2.6 million, or $0.07 per diluted share, compared to $18.7 million, or $0.50 per diluted share, for the year ended December 31, 2012. |
| |
| • | For the year ended December 31, 2013, Non-GAAP Adjusted Net Income was $44.3 million, or $1.16 per diluted share, compared to $37.2 million, or $1.00 per diluted share, for the year ended December 31, 2012. |
| |
| • | Our full year non-GAAP effective tax rate of 37% was lower than we anticipated primarily due to better than expected research and development tax credits. This lower non-GAAP effective tax rate increased our Non-GAAP Adjusted Net Income per Diluted Share for the year ended December 31, 2013, by approximately $0.08. |
| |
| • | As of December 31, 2013, we had cash and cash equivalents of $65.0 million and outstanding indebtedness of $223.8 million. |
Use of Non-GAAP Financial Measures
In our earnings releases, prepared remarks, conference calls, slide presentations, and webcasts, we may use or discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investors section of our web site at www.athenahealth.com.
Conference Call Information
To participate in athenahealth’s live conference call and webcast, please dial 877-853-5645 (or 408-940-3868 for international calls) using conference code No. 30311330, or visit the Investors section of our web site at www.athenahealth.com. A replay will be available for one week following the conference call at 855-859-2056 (and 404-537-3406 for international calls) using conference code No. 30311330. A webcast replay will also be archived on our website.
About athenahealth
athenahealth is a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination. athenahealth’s mission is to be caregivers’ most trusted service, helping them do well doing the right thing. For more information, please visit www.athenahealth.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements reflecting management’s expectations for future financial and operational performance and operating expenditures, expected growth, and business outlook; statements regarding the benefits of our service offerings and demands for our service offerings; statements regarding the potential expansion of our network; statements regarding our market opportunity; statements regarding changes in the health care industry, including an increased emphasis on cloud-based services for medical providers, and our positioning in regard to those changes; statements regarding our progress with client on-boarding and performance management; and statements found under our “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” section of this release. The forward-looking statements in this release do not constitute guarantees of future performance. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: our fluctuating operating results; our variable sales and implementation cycles, which may result in fluctuations in our quarterly results; risks associated with the acquisition and integration of companies and new technologies to achieve expected synergies, including those related to our ability to successfully integrate the services and offerings of Epocrates and realize the expected benefits; risks associated with our ability to realize the expected benefits from the purchase of the Arsenal on the Charles campus in Watertown, Massachusetts; risks associated with our expectations regarding our ability to maintain profitability; the impact of increased sales and marketing expenditures, including whether increased expansion in revenues is attained and whether impact on margins and profitability is longer term than expected; changes in tax rates or exposure to additional tax liabilities; the highly competitive industry in which we operate and the relative immaturity of the market for our service offerings; and the evolving and complex governmental and regulatory compliance environment in which we and our clients operate. Forward-looking statements may often be identified with words such as “we expect”, “we anticipate”, “upcoming” or similar indications of future expectations. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise. For additional disclosure regarding these and other risks faced by us, please see the disclosures contained
in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at www.athenahealth.com and on the SEC’s website at www.sec.gov.
Contact Info:
Dana Quattrochi
athenahealth, Inc. (Investors)
investorrelations@athenahealth.com
(617) 402-1329
Holly Spring
athenahealth, Inc. (Media)
media@athenahealth.com
(617) 402-1631
athenahealth, Inc.
CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands, except per share amounts) |
| | | | | | | | |
| | | December 31,
2013 | | December 31,
2012 |
| Assets | |
| |
|
| Current assets: | |
| |
|
| Cash and cash equivalents | | $ | 65,002 |
| | $ | 154,988 |
|
| Short-term investments | | — |
| | 38,092 |
|
| Current portion of restricted cash | | 3,000 |
| | 1,357 |
|
| Accounts receivable - net | | 87,343 |
| | 61,916 |
|
| Deferred tax assets | | 6,118 |
| | 6,907 |
|
| Prepaid expenses and other current assets | | 17,194 |
| | 10,924 |
|
| Total current assets | | 178,657 |
| | 274,184 |
|
| | | | | |
| Property and equipment - net | | 213,018 |
| | 54,035 |
|
| Capitalized software costs - net | | 29,987 |
| | 16,050 |
|
| Purchased intangible assets - net | | 168,364 |
| | 21,561 |
|
| Goodwill | | 198,049 |
| | 48,090 |
|
| Deferred tax assets | | — |
| | 11,759 |
|
| Investments and other assets | | 8,321 |
| | 2,773 |
|
| Total assets | | $ | 796,396 |
| | $ | 428,452 |
|
| | | | | |
| Liabilities & Stockholders’ Equity | |
| |
|
| Current liabilities: | |
| |
|
| Line of credit | | $ | 35,000 |
| | $ | — |
|
| Current portion of long-term debt | | 15,000 |
| | — |
|
| Accounts payable | | 3,930 |
| | 1,733 |
|
| Accrued compensation | | 44,444 |
| | 36,393 |
|
| Accrued expenses | | 24,297 |
| | 19,683 |
|
| Current portion of deferred revenue | | 27,002 |
| | 8,209 |
|
| Current portion of deferred rent | | 83 |
| | 799 |
|
| Total current liabilities | | 149,756 |
| | 66,817 |
|
| Deferred rent, net of current portion | | 1,478 |
| | 2,854 |
|
| Long-term debt, net of current portion | | 173,750 |
| | — |
|
| Deferred revenue, net of current portion | | 53,172 |
| | 45,515 |
|
| Long-term deferred tax liability - net | | 21,421 |
| | — |
|
| Other long-term liabilities | | 5,511 |
| | 1,618 |
|
| Total liabilities | | 405,088 |
| | 116,804 |
|
| | |
| |
|
| Stockholders’ equity: | |
| |
|
| Preferred stock, $0.01 par value: 5,000 shares authorized; no shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively | | — |
| | — |
|
| Common stock, $0.01 par value: 125,000 shares authorized; 38,600 shares issued and 37,322 shares outstanding at December 31, 2013; 37,572 shares issued and 36,294 shares outstanding at December 31, 2012 | | 387 |
| | 376 |
|
| Additional paid-in capital | | 380,967 |
| | 303,547 |
|
| Treasury stock, at cost, 1,278 shares | | (1,200 | ) | | (1,200 | ) |
| Accumulated other comprehensive loss | | (446 | ) | | (81 | ) |
| Retained earnings | | 11,600 |
| | 9,006 |
|
| Total stockholders’ equity | | 391,308 |
| | 311,648 |
|
| Total liabilities and stockholders’ equity | | $ | 796,396 |
| | $ | 428,452 |
|
athenahealth, Inc.
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited, in thousands, except per share amounts)
|
| | | | | | | | | | | | | | | | |
| | | Three Months Ended December 31, | | Twelve Months Ended December 31, |
| | | 2013 | | 2012 | | 2013 | | 2012 |
| Revenue: | | | | | | | | |
| Business services | | $ | 162,529 |
| | $ | 112,581 |
| | $ | 563,237 |
| | $ | 408,496 |
|
| Implementation and other | | 9,050 |
| | 3,723 |
| | 31,766 |
| | 13,775 |
|
| Total revenue | | 171,579 |
| | 116,304 |
| | 595,003 |
| | 422,271 |
|
| Expense: | | | | | | | | |
| Direct operating | | 62,852 |
| | 45,208 |
| | 238,672 |
| | 166,886 |
|
| Selling and marketing | | 37,947 |
| | 27,580 |
| | 149,488 |
| | 104,300 |
|
| Research and development | | 16,322 |
| | 9,263 |
| | 57,639 |
| | 33,792 |
|
| General and administrative | | 22,339 |
| | 14,952 |
| | 99,776 |
| | 57,025 |
|
| Depreciation and amortization | | 12,864 |
| | 7,677 |
| | 43,575 |
| | 25,641 |
|
| Total expense | | 152,324 |
| | 104,680 |
| | 589,150 |
| | 387,644 |
|
| Operating income | | 19,255 |
| | 11,624 |
| | 5,853 |
| | 34,627 |
|
| Other (expense) income: | | | | | | | | |
| Interest expense | | (1,319 | ) | | (143 | ) | | (3,905 | ) | | (407 | ) |
| Other income | | 136 |
| | 160 |
| | 283 |
| | 658 |
|
| Total other (expense) income | | (1,183 | ) | | 17 |
| | (3,622 | ) | | 251 |
|
| Income before income tax benefit (provision) | | 18,072 |
| | 11,641 |
| | 2,231 |
| | 34,878 |
|
| Income tax benefit (provision) | | (4,927 | ) | | (5,701 | ) | | 363 |
| | (16,146 | ) |
| Net income | | $ | 13,145 |
| | $ | 5,940 |
| | $ | 2,594 |
| | $ | 18,732 |
|
| Net income per share – Basic | | $ | 0.35 |
| | $ | 0.16 |
| | $ | 0.07 |
| | $ | 0.52 |
|
| Net income per share – Diluted | | $ | 0.34 |
| | $ | 0.16 |
| | $ | 0.07 |
| | $ | 0.50 |
|
| Weighted average shares used in computing net income per share: | | | | | | | | |
| Basic | | 37,262 |
| | 36,264 |
| | 36,856 |
| | 35,956 |
|
| Diluted | | 38,645 |
| | 37,420 |
| | 38,257 |
| | 37,133 |
|
athenahealth, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
|
| | | | | | | | |
| | | Year Ended December 31, |
| | | 2013 | | 2012 |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | | | |
| Net income | | $ | 2,594 |
| | $ | 18,732 |
|
| Adjustments to reconcile net income to net cash (used in) provided by operating activities: | | | | |
| Depreciation and amortization | | 61,853 |
| | 29,144 |
|
| Amortization of premium on investments | | 84 |
| | 1,270 |
|
| Provision for uncollectible accounts | | 791 |
| | 153 |
|
| Excess tax benefit from stock-based awards | | (6,910 | ) | | (14,179 | ) |
| Deferred income tax | | (7,044 | ) | | (890 | ) |
| Change in fair value of contingent considerations | | 76 |
| | (5,118 | ) |
| Stock-based compensation expense | | 42,648 |
| | 27,236 |
|
| Other reconciling adjustments | | (151 | ) | | (178 | ) |
| Changes in operating assets and liabilities: | | | | |
| Accounts receivable | | (4,190 | ) | | (12,764 | ) |
| Prepaid expenses and other current assets | | 3,283 |
| | 12,096 |
|
| Other long-term assets | | (66 | ) | | 111 |
|
| Accounts payable | | (233 | ) | | 13 |
|
| Accrued expenses | | (21 | ) | | 3,898 |
|
| Accrued compensation | | 5,775 |
| | 7,959 |
|
| Deferred revenue | | (3,090 | ) | | 2,969 |
|
| Deferred rent | | (2,091 | ) | | (239 | ) |
| Net cash provided by operating activities | | 93,308 |
| | 70,213 |
|
| CASH FLOWS FROM INVESTING ACTIVITIES: | | | | |
| Capitalized software development costs | | (29,123 | ) | | (15,657 | ) |
| Purchases of property and equipment | | (38,260 | ) | | (23,904 | ) |
| Proceeds from sales and disposals of property and equipment | | — |
| | 172 |
|
| Proceeds from sales and maturities of investments | | 56,245 |
| | 160,340 |
|
| Purchases of investments | | (2,000 | ) | | (118,919 | ) |
Payments on acquisitions, net of cash acquired
| | (410,161 | ) | | (5,798 | ) |
| Change in restricted cash | | (1,643 | ) | | 3,650 |
|
| Net cash used in investing activities | | (424,942 | ) | | (116 | ) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | | | |
| Proceeds from issuance of common stock under stock plans and warrants | | 31,133 |
| | 18,699 |
|
| Taxes paid related to net share settlement of restricted stock awards | | (12,075 | ) | | (4,248 | ) |
| Excess tax benefit from stock-based awards | | 6,910 |
| | 14,179 |
|
Proceeds from long-term debt
| | 200,000 |
| | — |
|
Proceeds from line of credit
| | 155,000 |
| | — |
|
Payments on line of credit
| | (120,000 | ) | | — |
|
| Payments on long-term debt and capital lease obligations | | (11,250 | ) | | — |
|
Net settlement of acquired company’s board of directors equity shares
| | (5,806 | ) | | — |
|
Debt issuance costs
| | (1,699 | ) | | — |
|
| Payment of contingent consideration accrued at acquisition date | | (525 | ) | | (1,550 | ) |
| Net cash provided by financing activities | | 241,688 |
| | 27,080 |
|
| Effects of exchange rate changes on cash and cash equivalents | | (40 | ) | | 30 |
|
| Net (decrease) increase in cash and cash equivalents | | (89,986 | ) | | 97,207 |
|
| Cash and cash equivalents at beginning of period | | 154,988 |
| | 57,781 |
|
| Cash and cash equivalents at end of period | | $ | 65,002 |
| | $ | 154,988 |
|
athenahealth, Inc.
STOCK-BASED COMPENSATION
(Unaudited, in thousands)
Set forth below is a breakout of stock-based compensation impacting the Consolidated Statements of Income for the three and twelve months ended December 31, 2013, and 2012:
|
| | | | | | | | | | | | | | | |
| | Three Months Ended December 31, | | Twelve Months Ended December 31, |
| | 2013 | | 2012 | | 2013 | | 2012 |
| Stock-based compensation charged to Consolidated Statements of Income: | | | | | | | |
| Direct operating | $ | 2,160 |
| | $ | 1,547 |
| | $ | 7,778 |
| | $ | 5,619 |
|
| Selling and marketing | 2,848 |
| | 2,312 |
| | 12,057 |
| | 7,717 |
|
| Research and development | 991 |
| | 306 |
| | 4,238 |
| | 3,213 |
|
| General and administrative | 2,925 |
| | 2,553 |
| | 18,575 |
| | 10,687 |
|
| Total stock-based compensation expense | 8,924 |
| | 6,718 |
| | 42,648 |
| | 27,236 |
|
| Amortization of capitalized stock-based compensation related to software development (1) | 347 |
| | 257 |
| | 1,027 |
| | 257 |
|
| Total | $ | 9,271 |
| | $ | 6,975 |
| | $ | 43,675 |
| | $ | 27,493 |
|
| | | | | | | | |
| |
| (1) | In addition, for the three and twelve months ended December 31, 2013, $0.5 million and $2.2 million, respectively, of stock-based compensation was capitalized in the line item Capitalized Software Costs in the Consolidated Balance Sheet for which $0.3 million and $1.0 million, respectively, of amortization was included in the line item Depreciation and Amortization Expense in the Consolidated Statements of Income. The amount of stock-based compensation related to capitalized software development costs in prior periods was not significant. |
athenahealth, Inc.
CASH, CASH EQUIVALENTS, AND AVAILABLE-FOR-SALE INVESTMENTS
(Unaudited, in thousands)
Set forth below is a breakout of total cash, cash equivalents, and available-for-sale investments as of December 31, 2013, and December 31, 2012:
|
| | | | | | | |
| | December 31, 2013 | | December 31, 2012 |
| | | | |
| Cash, cash equivalents | $ | 65,002 |
| | $ | 154,988 |
|
| Short-term investments | — |
| | 38,092 |
|
| Total | $ | 65,002 |
| | $ | 193,080 |
|
athenahealth, Inc.
REVENUE AND NON-GAAP ADJUSTED OPERATING INCOME BY BUSINESS
(Unaudited, in thousands)
Set forth below is a breakout of revenue and “Non-GAAP Adjusted Operating Income” by business for the three and twelve months ended December 31, 2013, and 2012:
|
| | | | | | | | | | | | | | | | |
| | | Three months ended | | Twelve months ended |
| | | December 31, | | December 31, |
| | | 2013 | | 2012 | | 2013 | | 2012 |
| Revenue: | | | | | | | |
| | Business services: | | | | | | | |
| | athenahealth | $ | 143,624 |
| | $ | 112,581 |
| | $ | 510,857 |
| | $ | 408,496 |
|
| | Epocrates | 18,905 |
| | — |
| | 52,380 |
| | — |
|
| | Implementation and other: | | | | | | | |
| | athenahealth | 5,406 |
| | 3,723 |
| | 22,029 |
| | 13,775 |
|
| | Other | 3,644 |
| | — |
| | 9,737 |
| | — |
|
| Total revenue | $ | 171,579 |
| | $ | 116,304 |
| | $ | 595,003 |
| | $ | 422,271 |
|
|
| | | | | | | | | | | | | | | | |
| | | Three months ended | | Twelve months ended |
| | | December 31, | | December 31, |
| | | 2013 | | 2012 | | 2013 | | 2012 |
| Non-GAAP Adjusted Operating Income: | | | | | | | |
| | athenahealth | $ | 29,636 |
| | $ | 19,699 |
| | $ | 69,441 |
| | $ | 65,479 |
|
| | Epocrates | 2,773 |
| | — |
| | 82 |
| | — |
|
| | Other | 1,710 |
| | — |
| | 4,439 |
| | — |
|
| Total Non-GAAP Adjusted Operating Income | 34,119 |
| | 19,699 |
| | 73,962 |
| | 65,479 |
|
| | Stock-based compensation expense | 8,924 |
| | 6,718 |
| | 42,648 |
| | 27,236 |
|
| | Integration and transaction costs | 397 |
| | — |
| | 9,024 |
| | — |
|
| | Amortization of capitalized stock-based compensation related to software development | 347 |
| | 257 |
| | 1,027 |
| | 257 |
|
| | Gain on early termination of lease | — |
| | — |
| | (2,468 | ) | | — |
|
| | Amortization of purchased intangible assets | 5,196 |
| | 1,100 |
| | 17,878 |
| | 3,359 |
|
| Total operating income | 19,255 |
| | 11,624 |
| | 5,853 |
| | 34,627 |
|
| Other (expense) income | (1,183 | ) | | 17 |
| | (3,622 | ) | | 251 |
|
| Income before income tax (provision) benefit | 18,072 |
| | 11,641 |
| | 2,231 |
| | 34,878 |
|
| Income tax (provision) benefit | (4,927 | ) | | (5,701 | ) | | 363 |
| | (16,146 | ) |
| Net income | $ | 13,145 |
| | $ | 5,940 |
| | $ | 2,594 |
| | $ | 18,732 |
|
athenahealth, Inc.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
TO COMPARABLE GAAP MEASURES
(Unaudited, in thousands, except per share amounts)
The following is a reconciliation of the non-GAAP financial measures used by us to describe our financial results determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”). An explanation of these measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”
While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of our business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP.
Please note that these figures may not sum exactly due to rounding.
Non-GAAP Adjusted Gross Margin
Set forth below is a presentation of our “Non-GAAP Adjusted Gross Profit” and “Non-GAAP Adjusted Gross Margin,” which represents Non-GAAP Adjusted Gross Profit as a percentage of total revenue.
|
| | | | | | | | | | | | | | | |
| (unaudited, in thousands) | Three Months Ended | | Twelve Months Ended |
| | December 31, | | December 31, |
| | 2013 | | 2012 | | 2013 | | 2012 |
| | | | | | | | |
| Total revenue | $ | 171,579 |
| | $ | 116,304 |
| | $ | 595,003 |
| | $ | 422,271 |
|
| Direct operating expense | 62,852 |
| | 45,208 |
| | 238,672 |
| | 166,886 |
|
| | | | | | | | |
| Total revenue less direct operating expense | 108,727 |
| | 71,096 |
| | 356,331 |
| | 255,385 |
|
Add: Stock-based compensation
allocated to direct operating expense | 2,160 |
| | 1,547 |
| | 7,778 |
| | 5,619 |
|
Add: Amortization of purchased intangible assets
allocated to direct operating expense | 2,777 |
| | 1,100 |
| | 10,617 |
| | 3,359 |
|
| | | | | | | | |
| Non-GAAP Adjusted Gross Profit | $ | 113,664 |
| | $ | 73,743 |
| | $ | 374,726 |
| | $ | 264,363 |
|
| | | | | | | | |
| Non-GAAP Adjusted Gross Margin | 66.2 | % | | 63.4 | % | | 63.0 | % | | 62.6 | % |
Non-GAAP Adjusted EBITDA
Set forth below is a reconciliation of our “Non-GAAP Adjusted EBITDA” and “Non-GAAP Adjusted EBITDA Margin,” which represents Non-GAAP Adjusted EBITDA as a percentage of total revenue.
|
| | | | | | | | | | | | | | | |
| (unaudited, in thousands) | Three Months Ended | | Twelve Months Ended |
| | December 31, | | December 31, |
| | 2013 | | 2012 | | 2013 | | 2012 |
| | | | | | | | |
| Total Revenue | $ | 171,579 |
| | $ | 116,304 |
| | $ | 595,003 |
| | $ | 422,271 |
|
| | | | | | | | |
| GAAP net income | 13,145 |
| | 5,940 |
| | 2,594 |
| | 18,732 |
|
| Add: Provision for (benefit) from income taxes | 4,927 |
| | 5,701 |
| | (363 | ) | | 16,146 |
|
| Add: Total other expense (income) | 1,183 |
| | (17 | ) | | 3,622 |
| | (251 | ) |
| Add: Stock-based compensation expense | 8,924 |
| | 6,718 |
| | 42,648 |
| | 27,236 |
|
| Add: Depreciation and amortization | 12,864 |
| | 7,677 |
| | 43,575 |
| | 25,641 |
|
| Add: Amortization of purchased intangible assets | 5,196 |
| | 1,100 |
| | 17,878 |
| | 3,359 |
|
| Add: Integration and transaction costs | 397 |
| | — |
| | 6,865 |
| | — |
|
| Add: Non-tax deductible transaction costs | — |
| | — |
| | 2,159 |
| | — |
|
| Less: Gain on early termination of lease | — |
| | — |
| | (2,468 | ) | | — |
|
| | | | | | | | |
| Non-GAAP Adjusted EBITDA | $ | 46,636 |
| | $ | 27,119 |
| | $ | 116,510 |
| | $ | 90,863 |
|
| | | | | | | | |
| Non-GAAP Adjusted EBITDA Margin | 27.2 | % | | 23.3 | % | | 19.6 | % | | 21.5 | % |
Non-GAAP Adjusted Operating Income
Set forth below is a reconciliation of our “Non-GAAP Adjusted Operating Income” and “Non-GAAP Adjusted Operating Income Margin,” which represents Non-GAAP Adjusted Operating Income as a percentage of total revenue.
|
| | | | | | | | | | | | | | | |
| (unaudited, in thousands) | Three Months Ended | | Twelve Months Ended |
| | December 31, | | December 31, |
| | 2013 | | 2012 | | 2013 | | 2012 |
| | | | | | | | |
| Total revenue | $ | 171,579 |
| | $ | 116,304 |
| | $ | 595,003 |
| | $ | 422,271 |
|
| | | | | | | | |
| GAAP net income | 13,145 |
| | 5,940 |
| | 2,594 |
| | 18,732 |
|
| Add: Provision for (benefit) from income taxes | 4,927 |
| | 5,701 |
| | (363 | ) | | 16,146 |
|
| Add: Total other expense (income) | 1,183 |
| | (17 | ) | | 3,622 |
| | (251 | ) |
| Add: Stock-based compensation expense | 8,924 |
| | 6,718 |
| | 42,648 |
| | 27,236 |
|
| Add: Amortization of capitalized stock-based compensation related to software development | 347 |
| | 257 |
| | 1,027 |
| | 257 |
|
| Add: Amortization of purchased intangible assets | 5,196 |
| | 1,100 |
| | 17,878 |
| | 3,359 |
|
| Add: Integration and transaction costs | 397 |
| | — |
| | 6,865 |
| | — |
|
| Add: Non-tax deductible transaction costs | — |
| | — |
| | 2,159 |
| | — |
|
| Less: Gain on early termination of lease | — |
| | — |
| | (2,468 | ) | | — |
|
| | | | | | | | |
| Non-GAAP Adjusted Operating Income | $ | 34,119 |
| | $ | 19,699 |
| | $ | 73,962 |
| | $ | 65,479 |
|
| | | | | | | | |
| Non-GAAP Adjusted Operating Income Margin | 19.9 | % | | 16.9 | % | | 12.4 | % | | 15.5 | % |
Non-GAAP Adjusted Net Income
Set forth below is a reconciliation of our “Non-GAAP Adjusted Net Income” and “Non-GAAP Adjusted Net Income per Diluted Share.”
|
| | | | | | | | | | | | | | | |
| (unaudited, in thousands) | Three Months Ended | | Twelve Months Ended |
| | December 31, | | December 31, |
| | 2013 | | 2012 | | 2013 | | 2012 |
| | | | | | | | |
| GAAP net income | $ | 13,145 |
| | $ | 5,940 |
| | $ | 2,594 |
| | $ | 18,732 |
|
| Add: Stock-based compensation expense | 8,924 |
| | 6,718 |
| | 42,648 |
| | 27,236 |
|
| Add: Amortization of capitalized stock-based compensation related to software development | 347 |
| | 257 |
| | 1,027 |
| | 257 |
|
| Add: Amortization of purchased intangible assets | 5,196 |
| | 1,100 |
| | 17,878 |
| | 3,359 |
|
| Add: Integration and transaction costs | 397 |
| | — |
| | 6,865 |
| | — |
|
| Less: Gain on early termination of lease | — |
| | — |
| | (2,468 | ) | | — |
|
| |
| |
| |
| |
|
| Sub-total of tax deductible items | 14,864 |
| | 8,075 |
| | 65,950 |
| | 30,852 |
|
| | | | | | | | |
| Less: Tax impact of tax deductible items (1) | (5,946 | ) | | (3,230 | ) | | (26,380 | ) | | (12,341 | ) |
| Add: Non-tax deductible transaction costs | — |
| | — |
| | 2,159 |
| | — |
|
| | | | | | | | |
| Non-GAAP Adjusted Net Income | $ | 22,063 |
| | $ | 10,785 |
| | $ | 44,323 |
| | $ | 37,243 |
|
| | | | | | | | |
| Weighted average shares - diluted | 38,645 |
| | 37,420 |
| | 38,257 |
| | 37,133 |
|
| | | | | | | | |
| Non-GAAP Adjusted Net Income per Diluted Share | $ | 0.57 |
| | $ | 0.29 |
| | $ | 1.16 |
| | $ | 1.00 |
|
| |
| (1) | Tax impact calculated using a statutory tax rate of 40%. |
|
| | | | | | | | | | | | | | | |
| (unaudited, in thousands) | Three Months Ended | | Twelve Months Ended |
| | December 31, | | December 31, |
| | 2013 | | 2012 | | 2013 | | 2012 |
| | | | | | | | |
| GAAP net income per share - diluted | $ | 0.34 |
| | $ | 0.16 |
| | $ | 0.07 |
| | $ | 0.50 |
|
| Add: Stock-based compensation expense | 0.23 |
| | 0.18 |
| | 1.11 |
| | 0.73 |
|
| Add: Amortization of capitalized stock-based compensation related to software development | 0.01 |
| | 0.01 |
| | 0.03 |
| | 0.01 |
|
| Add: Amortization of purchased intangible assets | 0.13 |
| | 0.03 |
| | 0.47 |
| | 0.09 |
|
| Add: Integration and transaction costs | 0.01 |
| | — |
| | 0.18 |
| | — |
|
| Less: Gain on early termination of lease | — |
| | — |
| | (0.06 | ) | | — |
|
| | | | | | | | |
| Sub-total of tax deductible items | 0.38 |
| | 0.22 |
| | 1.72 |
| | 0.83 |
|
| | | | | | | | |
| Less: Tax impact of tax deductible items (1) | (0.15 | ) | | (0.09 | ) | | (0.69 | ) | | (0.33 | ) |
| Add: Non-tax deductible transaction costs | — |
| | — |
| | 0.06 |
| | — |
|
| | | | | | | | |
| Non-GAAP Adjusted Net Income per Diluted Share | $ | 0.57 |
| | $ | 0.29 |
| | $ | 1.16 |
| | $ | 1.00 |
|
| | | | | | | | |
| Weighted average shares - diluted | 38,645 |
| | 37,420 |
| | 38,257 |
| | 37,133 |
|
| |
| (1) | Tax impact calculated using a statutory tax rate of 40%. |
Explanation of Non-GAAP Financial Measures
We report our financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of athenahealth and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.
Management defines “Non-GAAP Adjusted Gross Profit” as total revenue, less direct operating expense, plus (1) stock-based compensation expense allocated to direct operating expense and (2) amortization of purchased intangible assets allocated to direct operating expense, and “Non-GAAP Adjusted Gross Margin” as Non-GAAP Adjusted Gross Profit as a percentage of total revenue. Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends. Moreover, management believes that these measures enable investors and financial analysts to closely monitor and understand changes in our ability to generate income from ongoing business operations.
Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP net income before provision for (benefit) from income taxes, total other (income) expense, stock-based compensation expense, depreciation and amortization, amortization of purchased intangible assets, integration costs, transaction costs, and gain on early termination of lease and “Non-GAAP Adjusted EBITDA Margin” as Non-GAAP Adjusted EBITDA as a percentage of total revenue. Management defines “Non-GAAP Adjusted Operating Income” as the sum of GAAP net income before provision for (benefit) from income taxes, total other (income) expense, stock-based compensation expense, amortization of capitalized stock-based compensation related to software development, amortization of purchased intangible assets, integration costs, transaction costs, and gain on early termination of lease and “Non-GAAP Adjusted Operating Income Margin” as Non-GAAP Adjusted Operating Income as a percentage of total revenue. Management defines “Non-GAAP Adjusted Net Income” as the sum of GAAP net income before stock-based compensation expense, amortization of capitalized stock-based compensation related to software development, amortization of purchased intangible assets, integration costs, transaction costs, gain on early termination of lease and any tax impact related to these items, and “Non-GAAP Adjusted Net Income per Diluted Share” as Non-GAAP Adjusted Net Income divided by weighted average diluted shares outstanding. Management considers all of these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance.
Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:
| |
• | Stock-based compensation expense and amortization of capitalized stock-based compensation related to software development — excluded because these are non-cash expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred. |
| |
• | Amortization of purchased intangible assets — purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred. |
| |
• | Integration costs — integration costs are the severance and retention bonuses for certain employees relating to the Epocrates acquisition. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charge is incurred. |
| |
• | Transaction costs — transaction costs are non-recurring costs related to specific transactions. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred. |
| |
• | Gain on early termination of lease — gain on early termination of lease is a non-recurring gain related to the early termination of the Arsenal on the Charles lease. Accordingly, management believes that this gain does not have a direct correlation to future business operations, and therefore, this gain is not considered by management in making operating decisions. Management does not believe such gain accurately reflects the performance of our ongoing operations for the period in which such gain is recorded. |
